Results 191 to 200 of about 281,370 (287)

Antibody-drug conjugates in breast oncology: new standards, emerging challenges, and future directions. [PDF]

Ther Adv Med Oncol
Bhardwaj PV, Tarantino P, Schlam I.
europepmc   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry (AIO‐TRK‐0315)

International Journal of Cancer, EarlyView.
What's New? Estimating the risk of developing brain metastases may enable earlier diagnosis and treatment, potentially reducing morbidity and mortality. Using the prospective CRISP lung cancer registry, the authors developed and validated a point‐based classifier for the risk of developing first brain metastases in patients with advanced or metastatic ...
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller, Petra Hoffknecht, Andre Bethge, Arnd Nusch, Marcel Reiser, Christiane Bernhardt, Michael Bendel, Carolin Lennartz, Annette Fleitz, Martina Jänicke, Paula Ludwig, Annika Groth, Frank Griesinger, Michael Thomas, Wilfried E. E. Eberhardt, Martin Sebastian, for the CRISP Registry Group   +19 more
wiley   +1 more source

Genomic profiling and HER2-targeted therapy: a case series of Chinese salivary duct carcinoma patients and its clinical implications. [PDF]

Front Oncol
Huang X, Yu W, Li X, Cai B, Qu B, Chen J, Zhang P, Chen X, Liu Y, Feng S, Gui L, Liu F.   +11 more
europepmc   +1 more source

HER2 heterogeneity

The Breast, 2021
openaire   +2 more sources

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development. [PDF]

ESMO Gastrointest Oncol
Okemoto D, Nakayama I, Shitara K.
europepmc   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer. [PDF]

NPJ Breast Cancer
Tarantino P, Cha J, Binboga Kurt B, Chu X, Jovanović B, Zhou A, Hughes M, Russo D, DiLullo M, Wrabel E, Jeselsohn R, Lin NU, Carter J, Chen YS, Li T, Tayob N, Mittendorf EA, Schnitt SJ, Goel S, Tolaney SM.   +19 more
europepmc   +1 more source

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

Interdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li, Shun Wang, Guowei Zhao, Jiangtao Li, Xin Li, Bingning Wang, Yi Zhang, Mengfei Yao, Lei Guo, Jianming Ying, Wenbin Li   +10 more
wiley   +1 more source